We have evaluated the ability of bioballistic "gene gun" immunization of mice with plasmid DNA encoding clinically relevant tumor antigens to induce protective antitumor immunity. Mice immunized with plasmid cDNA encoding the cervical carcinomaassociated human papillomavirus 16-E7 gene product exhibited potent anti-E7-specific cytotoxic T lymphocytes and were protected completely against a subsequent challenge with the E7 ϩ C3 sarcoma. Of perhaps greater clinical interest, genetic immunization using cDNA encoding the normal, germline-encoded murine melanosomal protein tyrosinase-related protein-2 (TRP-2) resulted in delayed outgrowth of TRP-2 ϩ B16 melanoma in mice and was associated with an in vivo activation of TRP-2-specific cytotoxic T lymphocytes. Codelivery of plasmid cDNA encoding TRP-2 and the T helper 1-biasing cytokine murine interleukin-12 considerably enhanced the antitumor efficacy of these gene-based melanoma vaccines.
I n 1992, Tang et al 1 reported the surprising observation that particle-mediated gene transfer of an expression plasmid encoding human growth hormone into the skin of mice resulted not only in the systemic delivery of the molecule but also in the induction of antigen (Ag)-specific antibody responses. It was subsequently demonstrated that immunizations with purified plasmid DNA encoding influenza Ags, delivered either by particle bombardment using the gene gun or by needle injection into skin or muscle, promoted prophylactic immunity capable of protecting mice against a normally lethal challenge with live influenza virus. 2, 3 It is now well established that immunization with plasmid DNA may activate humoral immunity, Ag-specific CD8 ϩ cytotoxic T lymphocytes (CTLs), and CD4 ϩ T helper (Th) cell responses. 4 With the molecular identification of human tumorassociated Ags (TAAs) recognized by CTLs, [5] [6] [7] [8] [9] [10] [11] there has been increasing interest in the development of TAA cDNA immunization strategies for the active specific immunotherapy of cancer. Preclinical studies have shown that immunizing mice with plasmid DNA encoding foreign, highly immunogenic (i.e., xenogeneic) model Ags such as chicken ovalbumin 12 or ␤-galactosidase (␤-gal) 13 induces protective Ag-specific immune responses, allowing animals to reject transplanted tumor cell lines engineered to express these gene products. At present, it is unclear whether immunization with plasmid DNA encoding clinically relevant tumor Ags can induce antitumor immune responses that compare with those elicited in artificial model Ag systems. We chose to evaluate the ability of genetic immunization with cDNA encoding the tumor viral Ag human papillomavirus (HPV)16-E7 associated with cervical carcinoma or the normal, germline-encoded murine tyrosinase-related protein-2 (mTRP-2) associated with melanoma to protect mice against challenge with the syngeneic E7 ϩ C3 sarcoma or the TRP-2 ϩ B16 melanoma, respectively.
MATERIALS AND METHODS

Animals and cell lines
Female C57BL/6 (H-2 b ) mice, 6 -10 weeks old, were obtained from Charles River Laboratory (Raleigh, NC). All animals were maintained in a specific pathogen-free facility (Central Animal Facility, University of Pittsburgh . Cell lines were determined to be free of mycoplasma contamination (GeneProbe, Fisher Scientific, Pittsburgh, Penn) and were maintained in complete medium consisting of RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 0.1 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid, 50 M 2-mercaptoethanol, 100 international units/mL penicillin, and 100 g/mL streptomycin. RPMI 1640 was replaced with Dulbecco's modified Eagle's medium for the culture of B16 cells and with Ham's F12 medium for the culture of CHO cells. All cell culture reagents were purchased from Life Technologies (Gaithersburg, Md).
Peptides and peptide binding assays
The H-2D b binding peptide E7 49 -57 , which was derived from the HPV16-E7 protein, and the H-2K b -binding peptides mTRP-2 181-188 , mTRP-2 180 -189 , and mTRP-2 180 -188 , which were derived from the murine melanosomal protein TRP-2, were synthesized by standard fluorenylmethoxycarbonyl chemistry and purified by high-pressure liquid chromatography in the Peptide Synthesis Facility of the University of Pittsburgh Cancer Institute (Shared Resource). The peptide sequence was verified by tandem mass spectroscopy performed by the University of Pittsburgh Protein Sequencing Facility (Shared Resource). Peptides were dissolved in dimethyl sulfoxide (10 mM) and stored in 100-L aliquots at Ϫ20°C before use.
Peptide binding was measured by class I stabilization assays using transporter associated with Ag processing-deficient RMA-S cells as described previously. 16 Briefly, RMA-S cells were cultured at room temperature overnight, subsequently incubated with various concentrations of peptides for 1 hour at room temperature, and shifted to 37°C for 3 hours. Major histocompatibility complex class I expression was then assessed in indirect immunofluorescence assays using flow cytometry and a mouse monoclonal antibody (mAb) specific for H-2K b (HB41, American Type Culture Collection) followed by a fluorescein isothiocyanate-conjugated F(ab) 2 goat anti-mouse immunoglobulin G secondary antibody (Ab) (Sigma, St. Louis, Mo).
Plasmids
The plasmid pCI-E7 was constructed by subcloning the open reading frame of HPV16-E7 into the expression plasmid pCI (Promega, Madison, Wis) using polymerase chain reaction (PCR) techniques as described previously. 17 The plasmid pCI-mTRP-2 was constructed by PCR-cloning the cDNA coding for the murine melanosomal protein TRP-2 derived from the B16 melanoma cell line into the expression plasmid pCI. Briefly, total RNA was extracted from B16 cells using Trizol Reagent (Life Technologies). Reverse transcription was performed on 2 g of total RNA with anchored oligo(dT) primers. cDNA corresponding to 100 ng of total RNA was amplified for 30 cycles by PCR with primers designed to anneal to sequences 5Ј of the start and 3Ј of the stop codon and introduce SalI and NotI restriction sites, respectively. The amplified product was electrophoresed on a 1% agarose gel, purified, digested with SalI and NotI, and inserted into pCI. Inserts were sequenced in both directions to rule out mutations introduced by PCR. The plasmid pWRG3169 (pCMV-dmIL-12) containing coding sequences for the p35 and p40 subunits of murine interleukin-12 (mIL-12) driven by tandem cytomegalovirus (CMV) promoters has been described previously 18 and was kindly provided by Auragen/Powderject (Madison, Wis). For control purposes, pCI-␤-gal and pCI-EGFP were constructed by inserting fragments containing the ␤-gal gene (kindly provided by Auragen/Powderject) or the enhanced green fluorescent protein gene (Clontech, Palo Alto, Calif) into pCI. All vectors express only the Ag or cytokine of interest under a eukaryotic promoter. Plasmids were grown in Escherichia coli strain DH5␣ and purified using Qiagen Endofree Plasmid Maxi Kits (Qiagen, Chatsworth, Calif).
Construction of recombinant adenoviral vectors
Adenoviral vectors were constructed through Cre-lox recombination with reagents generously provided by Somatix (Alameda, Calif). A SnaBI-HpaI fragment containing part of the CMV promoter, EGFP N1 cDNA, and part of the simian virus 40 poly(A) derived from EGFP N1 (Clontech) was inserted into the shuttle vector pAdlox. The SalI-EGFP-NotI fragment of pAdlox-EGFP was replaced by a SalI-mTRP-2-NotI fragment from pCI-mTRP-2 to generate pAdlox-mTRP-2. Recombinant adenovirus was generated by the cotransfection of SfiI-digested pAdlox-EGFP or pAdlox-mTRP-2 and ⌿5 helper virus DNA into the adenoviral packaging cell line CRE8, propagated, and purified as described previously. 19 Ad-␤-gal, a recombinant adenovirus expressing ␤-gal, was used as a further control.
Immunodetection of mTRP-2
Rabbit antisera reactive with the C terminus of mTRP-1 (␣PEP1) and mTRP-2 (␣PEP8) were generously provided by Dr. V. Hearing 20 (National Institutes of Health, Bethesda, Md). For immunodetection, CHO cells stably transfected with pCI-mTRP-2 or pCI-␤-gal, MC38 transiently transduced with Ad-mTRP-2 or Ad-␤-gal, and B16 cells grown in mice in vivo were harvested by trypsinization and solubilized in lysis buffer (20 mM tris(hydroxymethyl)aminomethane, 150 mM NaCl, 2 mM ethylenediaminetetraacetic acid, and 0.5% Nonidet P-40, pH 7.5) containing protease inhibitors (Complete Protease Inhibitor Cocktail, Boehringer Mannheim, Indianapolis, Ind). Proteins were subjected to 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis and electroblotted onto nitrocellulose membranes. Membranes were blocked with 5% nonfat dry milk in Tween-Tris-buffered saline (TTBS) (0.5% Tween-20, 20 mM tris(hydroxymethyl)aminomethane, and 0.5 M NaCl, pH 7.5) for 1 hour and reacted with 1/1000 dilutions of ␣PEP1 or ␣PEP8 antiserum in TTBS plus 2% nonfat dry milk for 1 hour. Antibodies were detected with 1/200 dilutions of peroxidase-conjugated goat anti-rabbit immunoglobulin (BioRad, Richmond, Calif) in TTBS plus 2% nonfat dry milk for 1 hour and visualized by chemiluminescent detection (National Diagnostics, Atlanta, Ga) on x-ray film.
Cutaneous gene gun immunization
Plasmid DNA was precipitated onto 2.1-m gold particles at a density of 2 g of DNA per mg of particles. Gold particles and DNA were resuspended in 100 L of 0.05 M spermidine (Sigma), and DNA was precipitated by the addition of 100 L of 1 M CaCl 2 . Particles were washed with ethanol to remove H 2 O, resuspended in ethanol containing 0.075 mg/mL of polyvinylpyrrolidone (Sigma), and coated onto the inner surface of Tefzel tubing using a tube loader. The tubing was cut into 0.5-inch segments, each of which contained ϳ0.5 mg of gold coated with 1 g of plasmid DNA. For immunizations, the shaved skin of the abdomen was transfected in vivo by two shots with the Accell helium pulse gun at a pressure of 400 pounds per square inch, resulting in the delivery of a total of ϳ2 g of plasmid DNA. Immunizations were repeated after 2 and 4 weeks. The gold particles, tubing, tube loader, and Accell helium pulse gun were kindly provided by Auragen/ Powderject.
Tumor challenge, generation of cytotoxic effector populations, and cytotoxicity assays At 2 weeks after the last immunization, mice were injected with 2 ϫ 10 6 C3 tumor cells subcutaneously (s.c.) in the left flank or with 2 ϫ 10 4 pigmented B16 tumor cells s.c. in both flanks. Tumor growth was assessed every 3-4 days by measuring the largest perpendicular diameters and was recorded as tumor area (mm 2 ). Experiments included 5-10 mice per group and were performed three to five times. Alternatively, spleens from two to three immunized mice or from nonimmunized littermates were harvested and pooled. Splenocytes were restimulated in vitro for 5 days (4 ϫ 10 6 cells/well in 24-well plates) with synthetic peptide (0.1 g peptide/mL) or irradiated (10,000 rad) Ad-mTRP-2-transduced MC38 cells (10 4 cells/ well) in complete medium containing 25 international units of human IL-2 (Chiron, Emeryville, Calif). In vitro-restimulated lymphocytes were tested for their cytolytic reactivity against EL4 or RMA-S cells in the presence or absence of peptide in triplicate in standard 4-hour 51 Cr release assays using 96-well round-bottom plates as described previously.
17 B16 cells were pretreated for 48 hours with 10 ng/mL murine interferon-␥ before use in cytotoxicity assays. A total of 2 ϫ 10 6 target cells were radiolabeled with 100 Ci Na 2 51 CrO 4 (DuPont New England Nuclear, Bedford, Mass) for 1 hour at 37°C. Peptidepulsed targets were prepared by incubating cells with peptide at a concentration of 1 g/mL for 30 minutes at room temperature in 96-well plates before the addition of T cells in cytotoxicity assays.
RESULTS
Cutaneous gene gun immunization with plasmid DNA encoding the tumor viral Ag HPV16-E7 induces E7 peptide-specific CTLs and confers complete protective immunity In our initial experiments we assessed the efficacy of cutaneous gene gun immunizations using a highly immunogenic model Ag system. Groups of 5-10 mice were immunized with pCI-E7 or vector control (pCI). The induction of E7 peptide-specific CTLs was readily detected following in vitro restimulation of splenocytes with the synthetic E7 49 -57 peptide (Fig 1) . Tumor Agspecific CTL responses in these mice were associated with protective immunity against a normally lethal challenge with the E7 ϩ C3 sarcoma (Fig 2) . In total, 25 mice were immunized with pCI-E7, all of which rejected a challenge with the C3 sarcoma. In contrast, progressively growing tumors developed in 22 of 25 mice receiving cutaneous delivery of the pCI control plasmid as a vaccine.
Construction and functional assessment of plasmid DNA and recombinant adenovirus expressing mTRP-2 To investigate plasmid DNA immunization in a clinically relevant but less immunogenic experimental tumor model, we generated an expression plasmid (pCImTRP-2) expressing the germline-encoded, nonmutated murine melanosomal protein TRP-2. As outlined in Materials and Methods, total cDNA was isolated from the B16 melanoma cell line, and the cDNA encoding mTRP-2 was cloned using PCR methods. Automated DNA sequencing was performed on contiguous 500-base pair fragments of the cDNA in both directions to rule out mutations introduced by PCR. Our data are identi- Figure 1 . Gene gun immunization of mice with pCI-E7 leads to the induction of E7-specific CTLs. Mice were immunized with the indicated plasmid DNA, which was delivered to the skin using the gene gun as outlined in Materials and Methods. Animals were revaccinated after 2 weeks. At 1 week after the last immunization, two mice were sacrificed in each group; pooled splenocytes were restimulated for 5 days in vitro with the H-2D b -presented E7 49 -57 peptide. Cytotoxic T cell activity was measured in triplicate in standard 4-hour 51 Cr release assays against EL4 cells (A) and EL4 cells pulsed with the E7 49 -57 peptide (B). Results from one representative experiment of five are shown. The SD of the triplicate determinations for each effector to target (E:T) ratio was routinely Ͻ10%. 
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cal with the sequence published by Yang and colleagues, 29 which differs from the reported sequence of mTRP-2 in the GenBank database between nucleotides 1189 and 1192 (GCTG instead of CTGG). The mTRP-2 cDNA was then inserted into the adenoviral shuttle plasmid pAdlox to obtain pAdlox-mTRP-2. E1-substituted recombinant adenovirus was prepared using Crelox recombination. 17, 18 Transcription of mTRP-2 is driven by the CMV immediate early gene promoter in both the expression plasmid pCI-mTRP-2 and the recombinant adenovirus Ad-mTRP-2. To confirm the integrity of the mTRP-2 constructs, we stably transduced CHO cells with pCI-mTRP-2 or pCI-␤-gal, transiently transduced MC38 cells with Ad-mTRP-2 or Ad-␤-gal, and performed Western blot analysis with rabbit antisera reactive with the C terminus of mTRP-2 (Fig 3) . The nonglycosylated form of TRP-2 expressed in the transfectants has a molecular weight similar to the TRP-2 extracted from B16 melanoma cells grown in mice in vivo, whereas the molecular weight of the glycosylated form of TRP-2 seems to be lower than the naturally expressed TRP-2 gene product in B16 cells. This observation suggests that incomplete glycosylation may occur in CHO/MC38 genetically engineered to express TRP-2.
Gene gun immunization with plasmid DNA expressing mTRP-2 is associated with induction of TRP-2-specific CTLs
To assess the induction of Ag-specific CTLs, we restimulated splenocytes derived from vaccinated animals with the synthetic TRP-2 a80 -188 peptide. This nonapeptide differs from the peptide sequence reported by Yang et al 29 by the addition of one N-terminal amino acid and was chosen because of its higher binding affinity to H2-K b when compared with the TRP-2 181-188 peptide in RMA-S class I stabilization assays (Fig 4) . Peptidespecific cytotoxic reactivity was detected in in vitrorestimulated splenocytes derived from pCI-mTRP-2-immunized mice. As previously reported by Yang and colleagues, 29 we also routinely found considerable anti-TRP-2-specific cytotoxic T cell reactivity in controlimmunized mice (Fig 5) .
To confirm that the TRP-2 180 -188 peptide used in our studies is naturally processed and presented following transgenic expression of TRP-2, we performed in vitro restimulations of splenocytes with irradiated, syngeneic MC38 tumor cells transiently transduced by AdmTRP-2. MC38 cells were chosen because of high transfection efficiencies (data not shown) and a strong expression of TRP-2 following adenoviral transduction, as demonstrated in Figure 3 . Splenocytes harvested from TRP-2-immunized mice and restimulated with MC38-Ad-mTRP-2 clearly recognized target cells pulsed with the TRP-2 180 -188 peptide in CTL assays (Fig 6) . This finding suggests that the H-K b -binding TRP-2 180 -188 epitope is naturally processed and presented following transgenic expression in MC38 cells and confirms the immunogenicity of the melanosomal Ag. Similar to restimulations with synthetic TRP-2 180 -188 peptide, considerable CTL reactivity was also induced in splenocytes harvested from control-immunized mice. Importantly, splenocyte cultures restimulated with Ad-TRP-2-infected MC38 cells also displayed considerable cytolytic reactivity against B16 melanoma cells. Cytotoxic reactivity could be blocked by anti-CD8 mAb, but not by anti-CD4 mAb, supporting the class I-restricted nature of target cell killing (data not shown).
Gene gun immunization with plasmid DNA expressing mTRP-2 results in delayed tumor outgrowth after challenge with the B16 melanoma The principal goal of this study was to evaluate whether cutaneous gene gun vaccination with plasmid DNA expressing the germline-encoded murine melanosomal protein TRP-2 can induce effective antimelanoma immunity. Initial experiments involving groups of five mice immunized with pCI-mTRP-2 consistently demonstrated delayed tumor outgrowth when animals were challenged with the poorly immunogenic B16 melanoma compared with mice immunized with vector control (pCI). In a representative experiment, the mean tumor area (Ϯ SEM) measured 57 (Ϯ21) mm 2 compared with 108 (Ϯ34) mm 2 in the control group. No adverse autoimmune reactions were observed. In a minority of mice, transient depigmentation was noted at the site of tumor challenge and was associated with prolonged survival. Although some mice immunized with pCI-mTRP-2 remained tumor-free for a longer period of time before developing slowly growing tumors, complete tumor rejections (through day 60 after tumor challenge) were observed in only 2 of 24 mice (data not shown).
Administration of plasmid DNA expressing IL-12 as an adjuvant along with plasmid DNA expressing mTRP-2 enhances the induction of cell-mediated immunity and leads to increased protection against a B16 tumor challenge In an attempt to enhance the induction of antitumor immunity following DNA immunization, we simultaneously delivered plasmid DNA expressing the Th1-biasing cytokine mIL-12, a strong promoter of cellular immune responses, with pCI-mTRP-2. This regimen considerably enhanced the efficacy of TRP-2 plasmid DNA immunization, resulting in protection of a significantly elevated number of animals against a normally lethal B16 challenge (Fig 7) . The added protection offered by coadministration of the IL-12 gene is a result of specific immunization, because the control group of mice received the empty plasmid pCI along with the mIL-12 gene. In three experiments involving a total of 20 mice, 8 (40%) animals receiving TRP-2 plus IL-12 cDNA immunization remained tumor-free (through day 60 after tumor challenge), with 7 of 8 resistant against rechallenge with the B16 melanoma.
DISCUSSION
DNA-based immunization using expression plasmids or recombinant viral vectors encoding TAAs is currently being investigated for use in active specific tumor immunotherapy. A number of studies have demonstrated the efficacy of this approach in rodents using highly immunogenic model tumor Ags such as ovalbumin or Figure 5 . Induction of peptide-specific CTLs following gene gun immunization with pCI-mTRP-2. Mice were immunized with the indicated plasmid DNA, which was delivered to the skin using the gene gun. Immunizations were repeated after 2 and 4 weeks. At 1 week after the last immunization, two mice were sacrificed in each group; pooled splenocytes were restimulated in vitro for 5 days with the TRP-2 180 -188 peptide. Cytotoxic T cell activity was measured in standard 4-hour 51 Cr release assays against EL4 cells (A) and EL4 cells pulsed with the TRP-2 180 -188 peptide (B). Results from one representative experiment of three are shown. The SD of the triplicate determinations for each E:T ratio was routinely Ͻ10%. ␤-gal. 11, 12, [21] [22] [23] [24] Consistent with these findings, in the current report we have demonstrated the efficacy of gene gun immunization in a well-characterized murine model of cervical carcinoma. Immunizations with plasmid DNA expressing the immunogenic tumor viral Ag HPV16-E7 resulted in complete protection of mice against a normally lethal challenge with the HPV16-transformed C3 sarcoma. This model is of considerable clinical relevance because HPV16-E6 and -E7 are latently expressed in human cervical carcinoma and HLA-A2-binding peptide epitopes that can be recognized by CTLs have been identified. [25] [26] [27] Therefore, our results support the feasibility of DNA immunization targeting these gene products as a novel strategy for the immunotherapy of cervical cancer.
In subsequent studies, we turned to a murine model of melanoma. A number of human melanoma-associated Ags identified to date as CTL targets are lineagerestricted differentiation Ags, such as tyrosinase, 7 pmel17/glycoprotein 100, 8 MART-1, 9 or TRP-2; 10 these Ags derive from normal, germline-encoded genes. Recently, an H2-K b -restricted peptide-epitope derived from mTRP-2 was identified as the target for CTL lines reactive with the murine B16 melanoma. 28 This is analogous to the clinical situation in which peptide epitopes derived from TRP-2 have been described as CTL targets.
10,29 Therefore, we chose to evaluate whether genetic immunization targeting TRP-2 can induce effective antimelanoma immunity in the murine B16 melanoma model. Our results suggest that gene gun immunizations of mice with plasmid DNA encoding mTRP-2 were able to promote antitumor immune responses characterized by a delay in the onset of tumor growth. In contrast to immunizations with the highly immunogenic and "artificial" model Ags, 12, 13, [21] [22] [23] [24] we only observed tumor rejection in a minority of animals. These differences most likely reflect the stronger immunogenicity of many model tumor Ags compared with normal "self" lineageassociated Ags such as TRP-2. Similar results have been observed in murine studies involving DNA-based immunization with the tumor-specific Ag P1A, which is naturally expressed by the P815 mastocytoma. 23, 24 Although intramuscular injections with plasmid DNA expressing P1A considerably increased the survival rate following s.c. challenge with P815, they did not confer complete protection against P815 progression.
Codelivery of IL-12 cDNA has been demonstrated previously to enhance the cellular immunity induced by intramuscular injections of plasmid DNA encoding various viral Ags. 30 -32 Therefore, we attempted to enhance the efficacy of immunizations with plasmid DNA expressing mTRP-2 by coadministering plasmid DNA expressing mIL-12. Our results demonstrate that mice immunized with pCI-mTRP-2 plus pCMV-dmIL-12 displayed increased (versus the pCI-mTRP-2 control group) antitumor immunity, resulting in enhanced protection against a challenge with the B16 melanoma.
Our experiments, in which Ad-mTRP-2-transduced MC38 cells were successfully used to restimulate splenocytes harvested from TRP-2 or control plasmid immunized mice in vitro, suggest that tumor transfectants endogenously process and present the H-2K b -binding TRP-2 180 -188 epitope recognized by "autoreactive" CTLs. We do not know at this point whether altered glycosylation patterns, which were observed in MC38 cells (versus B16 melanoma) transduced with mTRP-2, differentially affect the processing and presentation of CTL-recognized epitopes. We were intrigued by the observation that CTL reactivity directed against the TRP-2 180 -188 peptide could easily be generated in control plasmid-immunized mice in vitro. This might be the result of the "artificially" high concentrations of CTL epitopes presented to T cells during in vitro restimulations with synthetic peptide, allowing for the activation of cross-reactive CTLs that exhibit a broad range of avidities for TRP-2-derived epitopes. Cross-reactive CTLs reactive with TRP-2 epitopes may also be present at high precursor frequencies in naive mice because of molecular mimicry with environmentally encountered immunogens, as noted previously for the human MART-1 Ag. 33 The induction of strong anti-TRP-2 CTL reactivity in vivo could potentially lead to the destruction of melanocytes and subsequent vitiligo. However, we did not observe coat color changes in mice following gene gun immunizations with TRP-2. In a minority of animals, local depigmentation was noted at the injection site after s.c. B16 challenge, and this was associated with prolonged survival.
In summary, our studies support the efficacy of plasmid-based immunization in two clinically relevant tumor Figure 7 . Administration of plasmid DNA encoding the Th1-biasing cytokine IL-12 along with pCI-mTRP-2 leads to enhanced resistance against B16 tumor challenge. Mice were immunized with the indicated plasmid DNAs, which were delivered to the skin using the gene gun as outlined in Materials and Methods. Animals were revaccinated after 2 and 4 weeks. At 1 week after the last immunization, mice were challenged s.c. with B16 tumor cells. The percentages of tumor-bearing animals following tumor challenge are depicted. These results are representative data of from one of three independent experiments performed using eight mice per group. model systems. We have also demonstrated for the first time that cutaneous gene gun immunization with plasmid DNA expressing a normal, germline-encoded melanocyte differentiation Ag can induce antimelanoma immunity in vivo, particularly in cases in which genedelivered adjuvants promoting cellular immune responses such as IL-12 are included in the vaccine.
